We are very much looking forward to the 2022 edition of the Neuro4D conference, which will take place in Mainz, Germany, on May 16 and 17. Priavoid GmbH will be represented by two speakers. Antje Willuweit will give a talk titled “Development of therapeutic substances for the disassembly of α-synuclein aggregates” at around 5 p.m. on Monday, April 16. Dieter Willbold will be speaking about our Alzheimer’s program PRI-002 on May 17 at around 1:30 p.m. His presentation is titled “PRI-002: towards clinical phase II – preclinical proof of concept and clinical phase I data”
We are looking forward to seeing many more exciting presentations and, of course, to seeing you!
Priavoid GmbH is a drug discovery company that was founded in September 2017 as a spin-off from Heinrich Heine University Düsseldorf and Forschungszentrum Jülich. The company develops novel all-d-peptide drug candidates for the treatment of neurodegenerative diseases such as Alzheimer’s, Parkinson’s, ALS, tauopathies and Huntington’s disease. The most advanced candidate is PRI-002 for Alzheimer’s disease. All drug candidates are designed for their anti-prionic mode of action. CEO: Philipp Bürling, Supervisory Board: Prof. Dr. Dr. h.c. Detlev Riesner (Chairman), Nobel Laureate Prof. Dr. Stanley Prusiner, Prof. Dr. Dieter Willbold.